Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119278799 | 11927879 | 9 | F | 20160113 | 20160711 | 20160119 | 20160714 | EXP | HU-PFIZER INC-2016022526 | PFIZER | 71.00 | YR | F | Y | 0.00000 | 20160714 | OT | HU | HU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119278799 | 11927879 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | Oral | 50 MG, 1X/DAY, CYCLIC, 4/2 SCHEME | Y | 21938 | 50 | MG | CAPSULE, HARD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119278799 | 11927879 | 1 | Clear cell renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119278799 | 11927879 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119278799 | 11927879 | Blood thyroid stimulating hormone increased | |
| 119278799 | 11927879 | Clear cell renal cell carcinoma | |
| 119278799 | 11927879 | Disease progression | |
| 119278799 | 11927879 | Goitre | |
| 119278799 | 11927879 | Periorbital oedema | |
| 119278799 | 11927879 | Spinal osteoarthritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119278799 | 11927879 | 1 | 20151221 | 0 |